2017
Moderators and predictors of response to behavior therapy for tics in Tourette syndrome
Sukhodolsky DG, Woods DW, Piacentini J, Wilhelm S, Peterson AL, Katsovich L, Dziura J, Walkup JT, Scahill L. Moderators and predictors of response to behavior therapy for tics in Tourette syndrome. Neurology 2017, 88: 1029-1036. PMID: 28202705, PMCID: PMC5384839, DOI: 10.1212/wnl.0000000000003710.Peer-Reviewed Original ResearchConceptsPredictors of responseChronic tic disorderTic reductionTic disordersPsychiatric disordersYale Global Tic Severity Scale-Total Tic ScoreTic severityTourette syndromeClinical Global Impressions-Improvement scoreCo-occurring psychiatric disordersAnxiety disordersSubgroup of patientsTotal tic scoreMain outcome measuresPredictors of outcomeBehavior therapyComprehensive Behavioral InterventionAttention-deficit/hyperactivity disorderPremonitory urge severityReduction of ticsCo-occurring attention-deficit/hyperactivity disorderGreater tic severityTIC characteristicsTic improvementClinical characteristics
2012
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 2012, 56: 391-400. PMID: 23086558, PMCID: PMC3537871, DOI: 10.1007/s00125-012-2753-4.Peer-Reviewed Original ResearchConceptsC-peptide responseType 1 diabetesImmune therapyHigh C-peptide responseCentral randomisation centreChronic autoimmune processPlacebo-treated participantsPlacebo-controlled trialPrimary outcome analysisCharacteristics of patientsC-peptide levelsSubgroup of patientsC-peptide productionTeplizumab groupClinical respondersAutoimmune processPrimary outcomeExogenous insulinMixed mealSubgroup analysisResultsThirty-fourInsulin secretionTreatment benefitBaseline imbalancesTeplizumab
2007
A Chitinase-like Protein in the Lung and Circulation of Patients with Severe Asthma
Chupp GL, Lee CG, Jarjour N, Shim YM, Holm CT, He S, Dziura JD, Reed J, Coyle AJ, Kiener P, Cullen M, Grandsaigne M, Dombret MC, Aubier M, Pretolani M, Elias JA. A Chitinase-like Protein in the Lung and Circulation of Patients with Severe Asthma. New England Journal Of Medicine 2007, 357: 2016-2027. PMID: 18003958, DOI: 10.1056/nejmoa073600.Peer-Reviewed Original ResearchConceptsSerum YKL-40 levelsYKL-40 levelsSeverity of asthmaYKL-40Chitinase-like proteinsParis cohortOral corticosteroid useCohort of patientsRescue inhaler useSubgroup of patientsCirculation of patientsCorticosteroid useSevere asthmaAirway remodelingClinical characteristicsExpiratory volumeAcidic mammalian chitinasePatient populationHigh serumAsthmaImmunohistochemical analysisPatientsAnimal modelsLocus of expressionMorphometric quantitation